R K Pharma
Privately held US-based pharmaceutical company focused on development, manufacturing and commercialization of generic pharmaceutical products and APIs. The group operates an integrated development, regulatory and manufacturing network with a state-of-the-art sterile finished dosage facility in Pearl River, NY and API/process R&D and manufacturing facilities in India. Core focus areas include sterile injectables, ophthalmic and dermal products, complex solid oral dosage forms, ANDA and 505(b)(2) development, and commercial distribution via affiliated commercial entities.
Industries
Nr. of Employees
large (251-1000)
R K Pharma
Pearl River, New York, United States, North America
Products
Diclofenac potassium tablets, 50 mg
Generic oral analgesic tablets listed as in-stock in company product listings.
Mitomycin injection vials (5 mg, 20 mg, 40 mg)
Sterile injectable antineoplastic product vials listed as in-stock.
Doxepin HCl tablets (3 mg, 6 mg)
Low-dose oral tablets listed as in-stock.
Leuprolide acetate injection, 14 mg/2.8 ml
Sterile depot injectable product listed in product pipeline.
Nicardipine hydrochloride injection, 25 mg/10 ml
Sterile injectable cardiovascular agent listed in inventory.
Mycophenolic acid delayed-release tablets (180 mg, 360 mg)
Delayed release oral solid dosage forms listed as available soon.
Diclofenac potassium tablets, 50 mg
Generic oral analgesic tablets listed as in-stock in company product listings.
Mitomycin injection vials (5 mg, 20 mg, 40 mg)
Sterile injectable antineoplastic product vials listed as in-stock.
Doxepin HCl tablets (3 mg, 6 mg)
Low-dose oral tablets listed as in-stock.
Leuprolide acetate injection, 14 mg/2.8 ml
Sterile depot injectable product listed in product pipeline.
Nicardipine hydrochloride injection, 25 mg/10 ml
Sterile injectable cardiovascular agent listed in inventory.
Mycophenolic acid delayed-release tablets (180 mg, 360 mg)
Delayed release oral solid dosage forms listed as available soon.
Services
End-to-end development and GMP manufacture of sterile injectables, ophthalmic and dry powder products using isolator technology and automated filling.
End-to-end development and GMP manufacture of sterile injectables, ophthalmic and dry powder products using isolator technology and automated filling.
Expertise Areas
- Generic pharmaceutical development
- Sterile injectable and ophthalmic manufacturing
- API process R&D and manufacturing
- Analytical testing and method development
Key Technologies
- Isolator-based aseptic filling
- Robotic automated filling systems
- Single-use fluid paths
- In-line weight and container closure leak detection
News & Updates
Announcement referencing the lease of 83,000 square feet at the former Pfizer complex in Pearl River for manufacturing operations.
Announcement of an up to $200 million investment from PAG to support RK Pharma's expansion.
Announcement of the acquisition of VGYAAN Pharmaceuticals LLC to expand the company's product portfolio and front-end capabilities.
Announcement referencing the lease of 83,000 square feet at the former Pfizer complex in Pearl River for manufacturing operations.
Announcement of an up to $200 million investment from PAG to support RK Pharma's expansion.
Announcement of the acquisition of VGYAAN Pharmaceuticals LLC to expand the company's product portfolio and front-end capabilities.